1. Protein Tyrosine Kinase/RTK
  2. Btk


Bruton tyrosine kinase (Btk) is a member of the Tec family kinases with a well-characterized role in B-cell antigen receptor (BCR)-signaling and B-cell activation.

Btk plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity. Btk is a kinase expressed exclusively in B cells and myeloid cells and has a well characterized, vital role in B cells highlighted by the human primary immune deficiency disease, X-linked agammaglobulinemia (XLA), which results from mutation in the Btk gene. Btk plays an essential role in the BCR signaling pathway. Antigen binding to the BCR results in B cell receptor oligomerization, Syk and Lyn kinase activation, followed by Btk kinase activation. Once activated, Btk forms a signaling complex with proteins such as BLNK, Lyn, and Syk and phosphorylates phospholipase C (PLC)γ2. This leads to downstream release of intracellular Ca2+ stores and propagation of the BCR signaling pathway through extracellular signal-regulated kinase and NF-κB signaling, ultimately resulting in transcriptional changes to foster B cell survival, proliferation, and/or differentiation.

Btk Related Products (28):

Cat. No. Product Name Effect Purity
  • HY-10997
    PCI-32765 Inhibitor 99.87%
    PCI-32765 is a selective, irreversible Btk inhibitor with IC50 value of 0.5 nM.
  • HY-17600
    Acalabrutinib Inhibitor 98.74%
    Acalabrutinib is a novel, potent, and highly selective BTK inhibitor, with an IC50 of 3 nM and EC50 of 8 nM in a human whole-blood CD69 B cell activation assay.
  • HY-19834
    GDC-0853 Inhibitor 99.50%
    GDC-0853 is a potent and orally BTK inhibitor.
  • HY-18012
    AVL-292 Inhibitor 99.95%
    AVL-292 is a potent inhibitor of Btk kinase activity (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s) in biochemical assays.
  • HY-15771
    ONO-4059 Inhibitor 98.31%
    ONO-4059 is a highly selective, orally bioavailable BTK inhibitor with a potency (IC50) of 2.2 nM.
  • HY-101766
    Btk inhibitor 2 Inhibitor
    Btk inhibitor 2 is a Bruton's tyrosine kinase (BTK) inhibitor extracted from patent US 20170224688 A1.
  • HY-15427
    GDC-0834 Inhibitor 98.02%
    GDC-0834 is a potent and selective BTK inhibitor. GDC-0834 inhibits BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC50 of 1.1 and 5.6 μM in mouse and rat, respectively.
  • HY-80002
    BMX-IN-1 Inhibitor 98.88%
    BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys496 in the BMX ATP binding domain with IC50 of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity.
  • HY-101215
    Evobrutinib Inhibitor 98.17%
    Evobrutinib is an inhibitor of Bruton's tyrosin kinase (Btk) inhibitor extracted from patent US20140162983 example 0174.
  • HY-18018
    RN486 Inhibitor 99.38%
    RN486 is a selective Btk inhibitor with an IC50 Value of 4.0 nM.
  • HY-100342
    Ibrutinib-biotin Inhibitor 99.67%
    Ibrutinib-biotin is a probe that consists of Ibrutinib linked to biotin via a long chain linker, extracted from patent WO2014059368A1 Compound 1-5, has an IC50 of 0.755-1.02 nM for BTK.
  • HY-18009
    LFM-A13 Inhibitor 99.70%
    LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM; shows no effects on JAK1 and JAK3, Src family kinase HCK, EGFR and IRK.
  • HY-101474
    (±)-Zanubrutinib Inhibitor 99.70%
    (±)-Zanubrutinib is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor.
  • HY-11999
    CGI-1746 Inhibitor
    CGI-1746 is a potent and highly selective inhibitor of the Btk with IC50 of 1.9 nM.
  • HY-101941
    SNS-062 Inhibitor 98.88%
    SNS-062 is a potent, noncovalent BTK and ITK inhibitor, with Kd of 0.3 nM and 2.2 nM, respectively; with IC50 of 24 nM for ITK.
  • HY-18951
    ONO-4059 analog Inhibitor 99.62%
    The product is the analog of ONO-4059, ONO-4059 is a highly potent and selective Btk inhibitor with an IC50 in the sub-nM range.
  • HY-80003
    QL47 Inhibitor 99.03%
    QL47 is a potent, selective and irreversible BTK kinase inhibitor with IC50 of 7 nM.
  • HY-15771A
    ONO-4059 hydrochloride Inhibitor 98.74%
    ONO-4059 is a selective and novel inhibitor of BTK with IC50 2.2 nm, ONO-4059 binds to BTK within B cells, thereby preventing B-cell receptor signaling and impeding B-cell development.
  • HY-10997A
    PCI-32765 Racemate Inhibitor
    PCI-32765 Racemate is the racemate of PCI-32765. PCI-32765 is a selective, irreversible Btk inhibitor with IC50 value of 0.5 nM.
  • HY-15427A
    GDC-0834 Racemate
    GDC-0834 Racemate is the racemate form of GDC-0834, which is a potent and selective BTK inhibitor with in vitro IC50s of 5.9 and 6.4 nM in biochemical and cellular assays, respectively.